“Sodium-Glucose Cotransporter 2 Inhibitors Lower Risk of Sight-Threatening Retinopathy in Type 2 Diabetes Patients Compared to DPP-4i, Pioglitazone, and Sulfonylureas”

https://pubmed.ncbi.nlm.nih.gov/38117497

Sodium-glucose cotransporter 2 inhibitors are associated with a lower risk of sight-threatening retinopathy compared to DPP-4i, pioglitazone, and sulfonylureas in patients with type 2 diabetes.